Efficacy News and Research

RSS

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

PTC Therapeutics, Inc., today announced that clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) were presented at the 20th International Congress of the World Muscle Society (WMS) in Brighton, U.K.

5 Oct 2015

Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

TEV-48125, a monoclonal anti-calcitonin-gene related peptide antibody, is well tolerated and effective in the prevention of high-frequency episodic migraine and chronic migraine, findings from two phase IIb studies show.

2 Oct 2015

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

A vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and huge commercial potential are attracting drug developers to the market.

1 Oct 2015

Researchers find neurons in human visual cortex that selectively react to intermediate colors

Researchers from Tohoku University's Research Institute of Electrical Communication and RIKEN BSI have found the presence of neurons in the human brain which can each selectively respond to an intermediate color; not just neurons of red, green, yellow and blue.

1 Oct 2015

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

AMO Pharma raises $25 million in private equity financing

AMO Pharma Limited, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, announced today that the company has raised $25 million in private equity financing from Woodford Investment Management.

30 Sep 2015

New Cerebral Aneurysm and AVMs modules broaden scope of NeuroVascular Quality Initiative

The Society of NeuroInterventional Surgery and M2S, a leading clinical registry provider, are pleased to announce the launch of the new Cerebral Aneurysm module for the NeuroVascular Quality Initiative (NVQI®), and the planned launch for the Cerebral Arteriovenous Malformations (AVMs) module in early October.

30 Sep 2015

Stony Brook Children's Hospital follows pain management protocols to treat pain in pediatric patients

Stony Brook Children's Hospital clinicians follow pain management protocols to proactively, preemptively, and consistently treat pain in each and every pediatric patient. Known as the Ouchless Approach to Pediatric Medicine, Margaret McGovern, MD, PhD, Physician-in-Chief, describes it as the cornerstone of treatment for pediatric patients at Stony Brook Children's.

30 Sep 2015

New gene therapy approach to treating DMD reduces symptoms, extends life span in mouse model

A gene therapy approach to treating the progressive muscle wasting disorder Duchenne muscular dystrophy (DMD) that does not replace the mutated DMD gene but instead delivers the gene for ITGA7, a protein in skeletal muscle, led to reduced symptoms and significantly extended life span in a mouse model of severe DMD. Over-expression of ITGA7 did not elicit an immune reaction, further supporting its potential as a novel treatment for DMD, according to a new study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

30 Sep 2015

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology

29 Sep 2015

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung

29 Sep 2015

Spiolto Respimat shown to be superior first line therapy over LABA/ICS for COPD

Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015

29 Sep 2015

Clinical trial initiated to determine feasibility, safety of focused ultrasound to treat depression

The first patient with depression has been treated with focused ultrasound. This procedure marks the beginning of a pilot clinical trial to determine the feasibility and safety of MR-guided focused ultrasound to non-invasively destroy a small volume of tissue deep in the brain - the anterior limb of the internal capsule - a well-established target for treating severe depression.

29 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Dr. Hauschka Skin Care achieves B Corporation Certification

Dr. Hauschka Skin Care, Inc. is proud to announce that it has achieved B Corporation Certification. This respected designation is awarded to companies meeting rigorous standards of social and environmental performance, accountability, and transparency.

29 Sep 2015

New drug may prevent malaria in pregnant women

Researchers at LSTM, working with colleagues of the Centres for Disease Control and Prevention (CDC) in Kenya and USA, and from the Kenya Medical Research Institution have found that a new drug may be more effective at preventing malaria in pregnant woman, especially where there is resistance to the current treatments.

29 Sep 2015

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Data presented today at the 2015 European Cancer Congress (ECC) demonstrates that the investigational immunotherapy atezolizumab may prevent progression of metastatic urothelial bladder cancer (mUBC) in all age groups by 2.1 months.

29 Sep 2015

European survey sheds light on decision-making criteria of physicians treating advanced lung cancer patients

Boehringer Ingelheim announced today results of a new European survey investigating therapy goals, prescribing habits and decision-making criteria of physicians treating patients with advanced lung cancer with adenocarcinoma histology after first-line chemotherapy.

29 Sep 2015

Research posters support utility of EKF’s PointMan DNA enrichment technology for rapid detection of lung cancer mutations

EKF, announces two research posters supporting application of PointMan™ DNA enrichment technology, for rapid and sensitive detection of lung cancer mutations.

From EKF Diagnostics 29 Sep 2015

Efficacy News and Research

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

Researchers find neurons in human visual cortex that selectively react to intermediate colors

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

AMO Pharma raises $25 million in private equity financing

New Cerebral Aneurysm and AVMs modules broaden scope of NeuroVascular Quality Initiative

Stony Brook Children's Hospital follows pain management protocols to treat pain in pediatric patients

New gene therapy approach to treating DMD reduces symptoms, extends life span in mouse model

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Spiolto Respimat shown to be superior first line therapy over LABA/ICS for COPD

Clinical trial initiated to determine feasibility, safety of focused ultrasound to treat depression

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Dr. Hauschka Skin Care achieves B Corporation Certification

New drug may prevent malaria in pregnant women

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

European survey sheds light on decision-making criteria of physicians treating advanced lung cancer patients

Research posters support utility of EKF’s PointMan DNA enrichment technology for rapid detection of lung cancer mutations

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News